drugset
drugset / Trial / NCT06107101

th2 Modulation CRSwNP

NCT06107101 ↗

Phase 4 Unknown 40 enrolled St. Paul's Sinus Centre
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Chronic rhinosinusitis (CRS) is a condition of persistent sinonasal mucosal inflammation which affects 11.9% of the US population. Mepolizumab is newly approved to treat chronic rhinosinusitis with nasal polyps (CRSwNP, the spaces inside nose and head are swollen and inflamed) and acts booking interleukin-5 (IL-5) a protein implicated in the inflammatory process. We aim to use Single-cell RNA sequencing (RNA-Seq, a method of genetically 'barcoding' cells to allow gene expression to be profiled at the level of individual cells) to study the effects of IL-5 blockade on the generation and maintenance of nasal adaptive immune responses, in CRS subjects.

Timeline

Start
2024-06-01
Primary completion
2025-01-01
Completion
2025-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 100 mg Subcutaneous

Indications

chronic rhinosinusitis